All I can read from this is that the drug is useless in severe patients and slightly better than placebo in moderate patients on average, but the huge standard deviations mean that patients in both cohorts are all over the place. Some placebo patients in the severe cohort improved by as much as 16 points.
At least the average improvement in moderate patients seems to be stable across trials at around 4+ SIB points. Maybe the next trial will shed some more light on this, but I have a feeling we won't get a satisfying answer until phase 3 results are out.
Thanks for posting this. I just reviewed it. It's interesting that in the moderate group the placebo group's scores did improve as well and over time. Don't know if that indicates they got better at taking the test/assessment but 13 weeks is still a short period of time.
With Alz patients time matters. So 6 months perhaps we don't see as much of an improvement in the placebo group. Although even better would be a decline in the placebo group over 6 months and not less of a rise in their scores.
I think one we can say for certain that once Alz becomes too severe, this clearly will not work.
News 
Market Data 
Discover 
